Dr. Epperla on CAR T-Cell Therapy in MCL

Narendranath Epperla, MBBS, MS
Published: Wednesday, Nov 15, 2017



Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with mantle cell lymphoma (MCL).

There is not currently enough data for CAR T-cell therapy in MCL, explains Epperla. Based on the impressive data in the diffuse large B-cell lymphoma setting, it would not be surprising if CAR T-cell therapy showed impressive results in MCL. Using CAR T-cell therapy pre- or post-allogeneic stem cell transplant still needs to be determined.
 


Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with mantle cell lymphoma (MCL).

There is not currently enough data for CAR T-cell therapy in MCL, explains Epperla. Based on the impressive data in the diffuse large B-cell lymphoma setting, it would not be surprising if CAR T-cell therapy showed impressive results in MCL. Using CAR T-cell therapy pre- or post-allogeneic stem cell transplant still needs to be determined.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x